NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq

Reuters

Sep 30

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq

NLS Pharmaceutics AG announced that its shareholders have approved the proposed merger with Kadimastem Ltd., clearing the final corporate milestone ahead of closing. The combined company will be renamed NewCelX Ltd. and is set to be listed on Nasdaq under the ticker symbol "NCEL." Upon completion, Kadimastem shareholders will own approximately 84.4% of the merged entity, while NLS shareholders will hold 15.6%. The merger brings together Kadimastem's advanced cell therapy programs, including a Phase 2a ALS study of AstroRx® and the IsletRx diabetes candidate, with NLS's expertise in CNS small-molecule therapies. The leadership team will be headed by Ronen Twito as Executive Chairman and CEO of NewCelX.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-093387), on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571534166"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571534166\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571534166?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571534166","market":"nz","top_or_hot":-1,"title":"NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NLS Pharmaceutics AG announced that its shareholders have approved the proposed merger with Kadimastem Ltd., clearing the final corporate milestone ahead of closing. The combined company will be renamed NewCelX Ltd. and is set to be listed on Nasdaq under the ticker symbol \"NCEL.\" Upon completion, Kadimastem shareholders will own approximately 84.4% of the merged entity, while NLS shareholders will hold 15.6%. The merger brings together Kadimastem's advanced cell therapy programs, including a Phase 2a ALS study of AstroRx® and the IsletRx diabetes candidate, with NLS's expertise in CNS small-molecule therapies. The leadership team will be headed by Ronen Twito as Executive Chairman and CEO of NewCelX.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-093387), on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NLS Pharmaceutics AG announced that its shareholders have approved the proposed merger with Kadimastem Ltd., clearing the final corporate milestone ahead of closing. The combined company will be renamed NewCelX Ltd. and is set to be listed on Nasdaq under the ticker symbol \"NCEL.\" Upon completion, Kadimastem shareholders will own approximately 84.4% of the merged entity, while NLS shareholders will hold 15.6%. The merger brings together Kadimastem's advanced cell therapy programs, including a Phase 2a ALS study of AstroRx® and the IsletRx diabetes candidate, with NLS's expertise in CNS small-molecule therapies. The leadership team will be headed by Ronen Twito as Executive Chairman and CEO of NewCelX.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-093387), on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NLSP","symbol_name":"NLS Pharmaceutics Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL2z7n77:1","article_id":"2571534166","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571534166","pubTimestamp":1759230930,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NLS Pharmaceutics AG announced that its shareholders have approved the proposed merger with Kadimastem Ltd., clearing the final corporate milestone ahead of closing. The combined company will be renamed NewCelX Ltd. and is set to be listed on Nasdaq under the ticker symbol \"NCEL.\" Upon completion, Kadimastem shareholders will own approximately 84.4% of the merged entity, while NLS shareholders will hold 15.6%. The merger brings together Kadimastem's advanced cell therapy programs, including a Phase 2a ALS study of AstroRx and the IsletRx diabetes candidate, with NLS's expertise in CNS small-molecule therapies. The leadership team will be headed by Ronen Twito as Executive Chairman and CEO of NewCelX.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NLSP":"NLS Pharmaceutics Ltd.","BK4007":"制药"},"translate_title":"NLS Pharmaceutics股东批准与Kadimastem合并，为NewCelX在纳斯达克上市铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NLSP":0.9},"content_text":"NLS Pharmaceutics Shareholders Approve Merger with Kadimastem, Paving Way for Launch of NewCelX on Nasdaq\n    \n\n        NLS Pharmaceutics AG announced that its shareholders have approved the proposed merger with Kadimastem Ltd., clearing the final corporate milestone ahead of closing. The combined company will be renamed NewCelX Ltd. and is set to be listed on Nasdaq under the ticker symbol \"NCEL.\" Upon completion, Kadimastem shareholders will own approximately 84.4% of the merged entity, while NLS shareholders will hold 15.6%. The merger brings together Kadimastem's advanced cell therapy programs, including a Phase 2a ALS study of AstroRx® and the IsletRx diabetes candidate, with NLS's expertise in CNS small-molecule therapies. The leadership team will be headed by Ronen Twito as Executive Chairman and CEO of NewCelX.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-093387), on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}